Metabolomics: A global biochemical approach to the study of central nervous system diseases

Neuropsychopharmacology

Volumn 34, Issue 1, 2009, Pages 173-186

  Kaddurah Daouk, Rima ^a   Krishnan, K Ranga Rama ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Metabolomics; Metabonomics; Neurodegenerative; Pharmacometabolomics; Psychiatric diseases

Indexed keywords

BIOLOGICAL MARKER;

BIOCHEMISTRY; CENTRAL NERVOUS SYSTEM DISEASE; DRUG RESEARCH; GENOMICS; HUMAN; METABOLISM; METABOLOMICS; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TRANSCRIPTOMICS;

ANIMALS; BIOLOGICAL MARKERS; BIOLOGICAL PSYCHIATRY; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; MENTAL DISORDERS; METABOLOMICS;

EID: 57649121825     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.174     Document Type: Review

References (100)

1. Ascherio A, LeWitt PA, Watts A, Kieburtz K, Rudolph A, Schwid SR, et al, and on behalf of the PSG DATA TOP investigators (2006). CSF as well as serum urate are predictors of Parkinson's disease progression. Movement Disorders Society International Congress on Parkinson's Disease and Movement Disorders, Kyoto (Abstract no. LB-2).
2. Banerjee P, Dasgupta A, Siakotas A, Dawson G (1992). Evidence for lipase abnormality: high levels of free and triacylglycerol forms of unsaturated fatty acids in neuronal ceroid-lipofuscinoses. Am J Med Genet 42: 549-554.
3. Berger GE, Wood SJ, Pantelis C, Velakoulis D, Wellard RM, McGorry PD (2002). Implications of lipid biology for the pathogenesis of schizophrenia. Aust N Z J Psychiatry 36: 355-366.
4. Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, Boorman E, M Matthews P et al (2007). Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 11: 255-260.
5. Bloch MH, Landeros-Weisenberger A, Sen S, Dombrowski P, Kelmendi B, Coric V et al (2008). Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: Systematic Review. Am J Med Genet B Neuropsychiatr Genet 147B: 850-858.
6. Bogdanov M, Matson W, Wang L, Matson T, Saunders-Pullman R, Bressman S et al (2008). Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131: 389-396.
7. Brambilla P, Perez J, Barale F, Schettini G, Soares JC (2003). GABAergic dysfunction in mood disorders. Mol Psychiatry 8: 721-737, 715.
8. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW et al (2002). Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 8: 1439-1444.
9. Brindle JT, Nicholson JK, Schofield PM, Grainger DJ, Holmes E (2003). Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 128: 32-36.
10. Coen M, Ruepp SU, Lindon JC, Nicholson JK, Pognan F, Lenz EM et al (2004). Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. J Pharm Biomed Anal 35: 93-105.
11. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
12. Crocker IP, Kenny LC, Thornton WA, Szabo C, Baker PN (2005). Excessive stimulation of poly(ADP-ribosyl)ation contributes to endothelial dysfunction in pre-eclampsia. Br J Pharmacol 144: 772-780.
13. Dauner M, Bailey JE, Sauer U (2001). Metabolic flux analysis with a comprehensive isotopomer model in Bacillus subtilis. Biotechnol Bioeng 76: 144-156.
14. de Graaf AA, Mahle M, Mollney M (2000). Determination of full 13C isotopomer distributions for metabolic flux analysis using heteronuclear spin echo difference NMR spectroscopy. J Biotechnol 77: 25035.
15. de Lau LM, Koudtall PJ, Hofman A, Breteler MM (2005). Serum uric cid levels and the risk of Parkinson disease. Ann Neurol 58: 797-800.
16. Delgado PL, Moreno FA (2000). Role of norepinephrine in depression. J Clin Psychiatry 61(Suppl 1): 5-12.
17. Dunne VG, Bhattachayya S, Besser M, Rae C, Griffin JL (2005). Metabolites from cerebrospinal fluid in aneurysmal subarachnoid haemorrhage correlate with vasospasm and clinical outcome: a pattern-recognition 1H NMR study. NMR Biomed 18: 24-33.
18. Fan TW-M, Lane AN (2007). Structure-based profiling of metabolites and isotopomers by NMR, Mol Cancer 6: 77.
19. Fan X, Bai J, Shen P (2005). Diagnosis of breast cancer using HPLC metabonomics fingerprints coupled with computational methods. Conf Proc IEEE Eng Med Biol Soc 6: 6081-6084.
20. Feuerstein TJ (2008). Presynaptic receptors for dopamine, histamine, and serotonin. Handb Exp Pharmacol 184: 289-338.
21. Fiehn O (2008). Extending the breadth of metabolite profiling by gas chromatography coupled to mass spectrometry. Trends Analyt Chem 27: 261-269.
22. Frye MA, Tsai GE, Huggins T, Coyle JT, Post RM (2007). Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry 61: 162-166.
23. Gardiner RM (2002). Clinical features and molecular genetics basis of the neuronal ceroid lipofuscinoses. Adv Neurol 89: 211-215.
24. German JB, Gillies LA, Smilowitz JT, Zivkovic AM, Watkins SM (2007). Lipidomics and lipid profiling in metabolomics. Curr Opin Lipidol 18: 66-71.
25. Gerner RH, Fairbanks L, Anderson GM, Young JG, Scheinin M, Linnoila M et al (1984). CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am J Psychiatry 141: 1533-1540.
26. Goebel HH, Sharp JD (1998). The neuronal ceroid-lipofuscinoses. Recent advances. Brain Pathol 8: 151-162.
27. Goodwin FK, Sack RL (1974). Central dopamine function in affective illness: evidence from precursors, enzyme inhibitors, and studies of central dopamine turnover. Adv Biochem Psychopharmacol 12: 261-279.
28. Han X, M Holtzman D, McKeel Jr DW, Kelley J, Morris JC (2002). Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 82: 809-818.
29. Harrigan G, Goodacre R (2003). Metabolic Profiling: Its Role in Biomarker Discovery and Gene Function Analysis. Kluwer Acad. Publ: Boston.
30. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC (2007). Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64: 193-200.
31. Hofmann SL, Atashband A, Cho SK, Das AK, Gupta P, Lu JY (2002). Neuronol ceroid lipofuscinoses caused by defects in soluble lysosomal enzymes (CLN1 and CLN2). Curr Mol Med 2: 423-437.
32. Holmes E, Tsang TM, Huang JT, Leweke FM, Koethe D, Gerth CW et al (2006). Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 3: e327.
33. Horrobin DF (1998). The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 30: 193-208.
34. Insel TM (2007). Devising prevention and treatment strategies for the nation's diverse populations with mental illness. Psychiatr Serv 58: 395.
35. Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden M, Borchelt D et al (2005). Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J Neurochem 95: 553-562.
36. Kaddurah-Daouk R (2006). Metabolic profiling of patients with schizophrenia. PLoS Med 3: e363.
37. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM (2008). Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48: 653-683.
38. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM et al (2007). Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 12: 934-945.
39. Kasa K, Otsuki S, Yamamoto M, Sato M, Kuroda H, Ogawa N (1982). Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biol Psychiatry 17: 877-883.
40. Kell DB (2004). Metabolomics and systems biology: making sense of the soup. Curr Opin Microbiol 7: 296-307.
41. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S et al (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608.
42. Klein C, Djarmati A, Hedrich K, Schafer N, Scaglione C, Marchese R et al (2005). PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. Eur J Hum Genet 13: 1086-1093.
43. Kristal BS, Kaddurah-Daouk R, Beal MF, Matson WR (2007a). Metabolomics: concept and potential neuroscience application. In: Handbook of Neurochemistry and Molecular Neurobiology: Brain Energetics. Integration of Molecular and Cellular Processes. Springer: New York. pp 889-912. 3rd Edition by editor Abel Lajtha.
44. Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR (2007b). Highperformance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol Biol 358: 159-174.
45. Kugaya A, Sanacora G (2005). Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 10: 808-819.
46. Lan MJ, McLoughlin GA, Griffin JL, Tsang TM, Huang JT, Yuan P et al (2008). Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug reatment of bipolar disorder. Mol Psychiatry [E pub ahead of print].
47. Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW (2000). Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 47: 586-593.
48. Lieberman JA, Koreen AR (1993). Neurochemistry and neuroendocrinology of schizophrenia, a selective review. Schizophr Bull 19: 371-429.
49. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
50. Lin MT, Beal MF (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787-795.
51. Lindon JC, Nicholson JK, Holmes E, Everett JR (2000). Metabonomics: metabolic processes studied by NMR spectroscopy of biofluids. Concepts Magn Reson 12: 289-320.
52. Lindon JC, Nicholson JK, Holmes E, Antti H, Bollard ME, Keun H et al (2003). Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol Appl Pharmacol 187: 137-146.
53. Lindon JC, Holmes E, Nicholson JK (2007). Metabonomics in pharmaceutical R&D. FEBS J 274: 1149-1151.
54. Mahadik SP, Yao JK, Phospholipids in schizophrenia (2006). In: Lieberman JA, Stroup TS, Perkins DO (eds). Textbook of Schizophrenia. American Psychiatric Publishing: Washington DC. pp 117-135.
55. Mahmood T, Silverstone T (2001). Serotonin and bipolar disorder. J Affect Disord 66: 1-11.
56. Mitchison HM, Lim MJ, Cooper JD (2004). Selectivity and types of cell death in the neuronal ceroid lipofuscinoses. Brain Pathol 14: 86-96.
57. Mitchison HM, Mole SE (2001). Neurodegenerative disease: the neuronal ceroid lipofuscinoses (Batten disease). Curr Opin Neurol 14: 795-803.
58. Miyamoto S, LaMantia AS, Duncan GE, Sullivan P, Gilmore JH, Lieberman JA (2003). Recent advances in the neurobiology of schizophrenia. Mol Interv 3: 27-39.
59. Morris HR (2005). Genetics of Parkinson's disease. Ann Med 37: 86-96.
60. Myers RH, MacDonald ME, Koroshetz WJ, Duyao MP, Ambrose CM, Taylor SA et al (1993). De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat Genet 5: 168-173.
61. Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J et al (2005). Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 113: 782-788.
62. Paige LA, Mitchell MW, Krishnan KR, Kaddurah-Daouk R, Steffens DC (2007). A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry 22: 418-423.
63. Patterson AD, Li H, Eichler GS, Krausz KW, Weinstein JN, Fornace Jr AJ et al (2008). UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem 80: 665-674.
64. Pears MR, Cooper JD, Mitchison HM, Mortishire-Smith RJ, Pearce DA, Griffin JL (2005). High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J Biol Chem 280: 42508-42514.
65. Petty F, Schlesser MA (1981). Plasma GABA in affective illness. A preliminary investigation. J Affect Disord 3: 339-343.
66. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
67. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A et al (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62.
68. Rotrosen J, Wolkin A (1987). Phospholipid and prostaglandin hypotheses of schizophrenia. In: Meltzer, NY(ed). Psychopharmacology, The Third Generation on Progress. Raven Press: New York. pp 759-764.
69. Rowland L, Shneider N (2001). Amyotrophic lateral scerosis. N Engl J Med 344: 1688-1700.
70. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C et al (2005). Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1: 101-108.
71. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R et al (2005). Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112: 3868-3875.
72. Sajda P (2006). Machine learning for detection and diagnosis of disease. Annu Rev Biomed Eng 8: 537-565.
73. Sanacora G, Saricicek A (2007). GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets 6: 127-140.
74. Serretti A, Calati R, Mandelli L, De Ronchi D (2006). Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets 7: 1659-1669.
75. Schildkraut JJ (1974). Biogenic amines and affective disorders. Annu Rev Med 25: 333-348.
76. Shin H, Markey MK (2006). A machine learning perspective on the development of clinical decision support systems utilizing mass spectra of blood samples. J Biomed Inform 39: 227-248.
77. Skosnik PD, Yao JK (2003). From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot Essent Fatty Acids 69: 367-384.
78. Sobczak S, Honig A, van Duinen MA, Riedel WJ (2002). Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies. Bipolar Disord 4: 347-356.
79. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M et al (1993). Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late onset Alzheimer disease. Proc Natl Acad Sci USA 90: 8098-8102.
80. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS et al (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90: 1977-1981.
81. Styczynski MP, Moxley JF, Tong LV, Walther JL, Jensen KL, Stephanopoulos GN (2007). Systematic identification of conserved metabolites in GC/MS data for metabolomics and biomarker discovery. Anal Chem 79: 966-973.
82. The Huntington's Disease Collaborative Research Group (1993). A novel gene containing a trinucleatide repeat that is expanded and unstable on Huntington's Disease chromosomes. Cell 72: 971-983.
83. Thomas B, Beal MF (2007). Parkinson's disease. Hum Mol Genet 16: R183-R194.
84. Tkachev D, Mimmack ML, Huffaker SJ, Ryan M, Bahn S (2007). Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int J Neuropsychopharmacol 10: 557-563.
85. Tolstikov VV, Fiehn O, Tanaka N (2007). Application of liquid chromatography-mass spectrometry analysis in metabolomics: reversed-phase monolithic capillary chromatography and hydrophilic chromatography coupled to electrospray ionization-mass spectrometry. Methods Mol Biol 358: 141-155.
86. Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E (2008). Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 31: 7-20.
87. Tsang TM, Huang JT, Holmes E, Bahn S (2006). Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. J Proteome Res 5: 756-760.
88. Underwood B, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C et al (2006). Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 129: 877-886.
89. van der Greef J, Martin S, Juhasz P, Adourian A, Plasterer T, Verheij ER et al (2007). The art and practice of systems biology in medicine: mapping patterns of relationships. J Proteome Res 6: 1540-1559.
90. van Doorn M, Vogels J, Tas A, van Hoogdalem EJ, Burggraaf J, Cohen A et al (2007). Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in type 2 diabetes mellitus patients and healthy volunteers. Br J Clin Pharmacol 63: 562-574.
91. Wang C, Kong H, Guan Y, Yang J, Gu J, Yang S et al (2005). Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal Chem 77: 4108-4116.
92. Watkins SM (2004). Lipomic profiling in drug discovery, development and clinical trial evaluation. Curr Opin Drug Discov Devel 7: 112-117.
93. Watson AD (2006). Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res 47: 2101-2111.
94. Weiden PJ, Buckley PF (2007). Reducing the burden of side effects during long term antipsychotic therapy: the role of switching medications. J Clin Psychiatry 68: 14-23.
95. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M (2005). IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 10: 538-544.
96. Wiest MM, Watkins SM (2007). Biomarker discovery using high-dimensional lipid analysis. Curr Opin Lipidol 18: 181-186.
97. Wisniewski KE, Zhong N, Philippart M (2001). Pheno/genotypic correlations of neuronal ceroid lipofuscinoses. Neurology 57: 576-581.
98. Yang J, Xu G, Zheng Y, Kong H, Pang T, Lv S et al (2004). Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J Chromatogr B Analyt Technol Biomed Life Sci 813: 59-65.
99. Younes-Mhenni S, Frih-Ayed M, Kerkeni A, Bost M, Chazot G (2007). Peripheral blood markers of oxidative stress in Parkinson's disease. Eur Neurol 58: 78-83.
100. Yuan K, Kong H, Guan Y, Yang J, Xu G (2007). A GC-based metabonomics investigation of type 2 diabetes by organic acids metabolic profile. J Chromatogr B Analyt Technol Biomed Life Sci 850: 236-240.